Inventor
GREMBECKA JOLANTA
US32 patents
⚠️ This page may combine multiple inventors who share the name “GREMBECKA JOLANTA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV MICHIGAN REGENTS
18 patentsUS9505782B2Nov 29, 2016
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
UNIV MICHIGAN REGENTS24 citations93
US9505781B2Nov 29, 2016
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
UNIV MICHIGAN REGENTS16 citations91
US10246464B2Apr 2, 2019
Thienopyrimidine and thienopyridine compounds and methods of use thereof
UNIV MICHIGAN REGENTS9 citations84
US11147885B2Oct 19, 2021
ASH1L inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS5 citations83
US10632209B2Apr 28, 2020
ASH1L inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS9 citations83
US10160769B2Dec 25, 2018
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
UNIV MICHIGAN REGENTS10 citations82
US11833210B2Dec 5, 2023
ASH1L inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS1 citations72
US11786602B2Oct 17, 2023
ASH1L degraders and methods of treatment therewith
UNIV MICHIGAN REGENTS1 citations72
US11110177B2Sep 7, 2021
ASH1L degraders and methods of treatment therewith
UNIV MICHIGAN REGENTS2 citations72
US11319302B2May 3, 2022
PRC1 inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS2 citations66
USRE49687EOct 10, 2023
Thienopyrimidine and thienopyridine compounds and methods of use thereof
UNIV MICHIGAN REGENTS1 citations62
US12521442B2Jan 13, 2026
ASH1L inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS0 citations61
US12285490B2Apr 29, 2025
ASH1L degraders and methods of treatment therewith
UNIV MICHIGAN REGENTS0 citations61
US12466813B2Nov 11, 2025
PRC1 inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS0 citations55
US12364688B2Jul 22, 2025
NSD family inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS0 citations53
US11324729B2May 10, 2022
NSD family inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS0 citations53
US11883381B2Jan 30, 2024
ASH1L inhibitors and methods of treatment therewith
UNIV MICHIGAN REGENTS0 citations44
US11858925B2Jan 2, 2024
GAS41 inhibitors and methods of use thereof
UNIV MICHIGAN REGENTS0 citations41
KURA ONCOLOGY INC
8 patentsUS11673898B2Jun 13, 2023
Substituted inhibitors of menin-MLL and methods of use
KURA ONCOLOGY INC6 citations85
US10781218B2Sep 22, 2020
Substituted inhibitors of menin-MLL and methods of use
KURA ONCOLOGY INC16 citations85
US10752639B2Aug 25, 2020
Bridged bicyclic inhibitors of menin-MLL and methods of use
KURA ONCOLOGY INC8 citations84
US10588907B2Mar 17, 2020
Methods and compositions for inhibiting the interaction of menin with MLL proteins
KURA ONCOLOGY INC6 citations84
US10174041B2Jan 8, 2019
Methods and compositions for inhibiting the interaction of menin with MLL proteins
KURA ONCOLOGY INC11 citations84
US10077271B2Sep 18, 2018
Methods and compositions for inhibiting the interaction of menin with MLL proteins
KURA ONCOLOGY INC14 citations84
US11542248B2Jan 3, 2023
Methods and compositions for inhibiting the interaction of menin with MLL proteins
KURA ONCOLOGY INC4 citations74
US11555041B2Jan 17, 2023
Bridged bicyclic inhibitors of menin-MLL and methods of use
KURA ONCOLOGY INC1 citations62